Domain-alteration chimeras, specifically experimental molecules like DALTAC-1 and PBITE-1, have emerged as a novel therapeutic strategy to target previously undruggable cancer-driving proteins such as ERG and the androgen receptor in prostate cancer.
Published in Nature on Wednesday the preclinical research demonstrates that linking regulatory proteins into abnormal physical configurations achieves potent antitumor activity while sparing normal cells.
Researchers at the University of Michigan and the Rogel Cancer Center investigated how bifunctional small molecules can alter protein domains to dismantle oncogenic transcription complexes. The genetic rearrangement involving the TMPRSS2 and ERG genes occurs in roughly half of prostate cancer cases among patients of European ancestry, promoting tumor cell growth and migration.
For years, ERG was considered undruggable because it lacked the deep molecular pockets where typical medications attach. By utilizing domain-alteration chimeras, the team demonstrated that targeting these previously inaccessible binding interfaces is biologically feasible.
“Although we were the first to identify the gene fusion as a driver of prostate cancer, it was challenging to find a drug target for ERG,” said Arul Chinnaiyan, M.D., Ph.D., S.P.
The experimental strategy utilizes chemically induced proximity to bridge transcriptional regulators like p300/CBP with the androgen receptor or ERG variants. This forced interaction disrupts downstream oncogenic signaling pathways critical for castration-resistant prostate cancer proliferation. The preclinical evaluation spanned multiple experimental platforms, including human-derived prostate cancer cell lines, murine models, and three-dimensional organoids.
Across these testing platforms, the chimeras showed strong selectivity for tumor cells over normal cellular populations. SciTechDaily reported that the compound PBITE-1 interfered with ERG activity, triggered cancer cell death, and reduced the ability of cancer cells to invade surrounding tissue in laboratory models.
Senior investigator Shaomeng Wang, PhD, directs the Michigan Center for Therapeutic Innovation, working alongside co-first authors Jie Luo from the Chinnaiyan laboratory and Jianzhang Yang from the Wang laboratory.
“This work shows that instead of treating all prostate cancer as one disease, we have the potential to personalize therapy for subtypes of prostate cancer,” Chinnaiyan explained.
| Compound | Primary Target | Experimental Model | Observed Preclinical Effect |
|---|---|---|---|
| DALTAC-1 | Androgen Receptor & p300/CBP | VCaP, LNCaP, and Organoids | Disruption of oncogenic transcription complexes |
| PBITE-1 | ERG Fusion Protein | Prostate Cancer Cell Lines & Mouse Models | Inhibition of ERG activity and reduction of cell migration |
“Although it is unlikely that PBITE-1 is ready to become a drug any time soon, this study shows that ERG is a druggable target,” Chinnaiyan told SciTechDaily.
While these durable preclinical responses point toward a viable pathway for advanced malignancies, investigators emphasize that the research remains at an early exploratory stage. Both research teams are actively working to refine candidates suitable for future human clinical trials. Translating these findings from cellular and animal models to human clinical settings will require extensive pharmacokinetic optimization and rigorous toxicology profiling.
Looking beyond prostate oncology, the research team said that the strategy of reprogramming protein interaction networks could provide a generalizable framework for anticancer drug development across other tumor types. However, no human clinical trial data currently exist, and further independent validation is required before these agents can be evaluated in clinical settings.
Always consult a qualified healthcare professional regarding any medical condition.
